BİYOERİYEBİLEN STENTLER

Öz

Perkütan koroner girişim yöntemleri son dekadda oldukça hızlı bir gelişim göstermiştir. Bu gelişimin en son aşaması ise biyoeriyebilen stent teknolojisidir. Biyoeriyebilen stentlerin metalik yabancı iskeleti olmaması nedeniyle vasküler inflamasyon, restenoz, stent trombozu ve neoaterosklerozu azaltma gibi potensiyel avantajları olabileceği düşünülse de yapılan prospektif çalışmaların orta dönem sonuçları büyük hayal kırıklığı yaratmıştır. Günümüzde bu teknolojinin klinik kullanıma yaygın olarak sunulması için geliştirme faaliyetleri sürmektedir. Bu derlemede biyoeriyebilen stent teknolojisi ile ilgili pre-klinik ve klinik değerlendirmelere yer verilmiştir.

Anahtar Kelimeler

• Biyoeriyebilen iskelet,perkütan koroner girişim

Kaynakça

1. . Gruntzig A. Transluminal dilatation of coronary-artery stenosis. Lancet (London, England). 1978;1(8058):263
2. 2. Gruntzig AR, Senning A, Siegenthaler WE. Nonoperative dilatation of coronaryartery stenosis: Percutaneous transluminal coronary angioplasty. The New England Journal of Medicine. 1979;301(2):61–8
3. 3. Sigwart U, Urban P, Golf S, Kaufmann U, Imbert C, Fischer A, Kappenberger L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78(5 Pt 1):1121–27.
4. 4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85(3):916–27
5. 5. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, , Emanuelsson H, Marco J, Legrand V, Materne P, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. Benestent Study Group. The New England Journal of Medicine. 1994;331(8):489–95
6. 6. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine. 1994;331(8):496–501
7. 7. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, Turco M, Caputo R, Bergin P, Greenberg J, Popma JJ, Russell ME; TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. The New England Journal of Medicine. 2004;350(3):221–31
8. 8. Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. The New England Journal of Medicine. 2002;346(23):1773–80

9. 9. Tenekecioglu E, Farooq V, Bourantas CV, Silva RC, Onuma Y, Yılmaz M, Serruys PW. Bioresorbable scaffolds: a new paradigm in percutaneous coronary intervention. BMC Cardiovascular Disorders. 2016;16:38.
10. 10. Iqbal J, Onuma Y, Ormiston J, Abizaid A, Waksman R, Serruys P. Bioresorbable scaffolds: Rationale, current status, challenges, and future. European Heart Journal. 2014;35(12):765–76.
11. 11. Zhang Y, Bourantas CV, Farooq V, Muramatsu T, Diletti R, Onuma Y, et al. Bioresorbable scaffolds in the treatment of coronary artery disease. Medical Devices (Auckland, NZ). 2013;6:37–48
12. 12. Onuma Y, Serruys PW. Bioresorbable scaffold: The advent of a new era in percutaneous coronary and peripheral revascularization? Circulation. 2011;123(7):779–97.
13. 13. Verheye S, Ormiston JA, Stewart J, Webster M, Sanidas E, Costa R, et al. A next-generation bioresorbable coronary scaffold system: From bench to first clinical evaluation: 6- and 12-month clinical and multimodality imaging results. JACC Cardiovascular Interventions. 2014;7(1):89–99
14. 14. Nikolsky E, Mehran R, Dangas G, Fahy M, Na Y, Pocock SJ, et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. European Heart Journal. 2007;28(16):1936–45
15. 15. Kitabata H, Waksman R, Warnack B. Bioresorbable metal scaffold for cardiovascular application: current knowledge and future perspectives. Cardiovasc Revasc Med 2014;15:109-16
16. 16. Diletti R, Serruys PW, Farooq V, et al. ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatment of subjects with ischemic heart disease caused by de novo native coronary artery lesions: rationale and study design. Am Heart J 2012;164:654-63
17. 17. Kereiakes DJ, Ellis SG, Popma JJ, et al. Evaluation of a fully bioresorbable vascular scaffold in patients with coronary artery disease: design of and rationale for the ABSORB III randomized trial. Am Heart J 2015;170:641-51
18. 18. Biscaglia S, Ugo F, Ielasi A, et al. Bioresorbable Scaffold vs. Second Generation Drug Eluting Stent in Long Coronary Lesions requiring Overlap: A Propensity-Matched Comparison (the UNDERDOGS study). Int J Cardiol 2016;208:40-5
19. 19. Sabaté M, Windecker S, Iñiguez A, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37(3):229-40
20. 20. Kimura T, Kozuma K, Tanabe K, et al. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36(47):3332-42
21. 21. Serruys PW, Chevalier B, Sotomi Y, et al. Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3-year, randomized, controlled, single-blind, multicenter trial. Lancet. 2016; Epub ahead of print.
22. 22. Ellis SG, Kereiakes DJ, Metzger C, et al., on behalf of the ABSORB III Investigators. The 2-year Clinical Outcomes of the ABSORB III Trial:. Presented by Dr. Stephen Ellis at the American College of Cardiology Annual Scientific Session (ACC 2017), Washington, DC, March 18, 2017